The impact of baseline liver histology on virologic response to interferon-α2b+/-ρribavirin therapy in patients with chronic hepatitis C.

被引：0
|
作者：
Fang, JS
Goodman, ZD
Albrecht, JK
Yao, R
Garaud, JJ
Lau, JN
机构：
[1] Schering Plough Corp, Res Inst, Kenilworth, NJ 07033 USA
[2] Armed Forces Inst Pathol, Washington, DC 20306 USA
来源：
HEPATOLOGY | 1999年 / 30卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
572
引用
收藏
页码：303A / 303A
页数：1
相关论文
共 50 条
  • [41] Interferon-α-2b+ribavirin for the treatment of chronic hepatitis C in non-responders to interferon-α-monotherapy
    Tromm, A
    Greving, I
    Griga, T
    Mankel, K
    Hüppe, D
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2000, 38 (02): : 159 - 164
  • [42] Polymorphisms of interferon-λ4 and IL28B - effects on treatment response to interferon/ribavirin in patients with chronic hepatitis C
    Staettermayer, A. F.
    Strassl, R.
    Maieron, A.
    Rutter, K.
    Stauber, R.
    Strasser, M.
    Beinhardt, S.
    Datz, C.
    Scherzer, T. -M.
    Steindl-Munda, P.
    Gschwantler, M.
    Trauner, M.
    Hofer, H.
    Ferenci, P.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2014, 39 (01) : 104 - 111
  • [43] Efficacy and safety of combination therapy with interferon-α2b and ribavirin for chronic hepatitis C in HIV-infected patients
    Landau, A
    Batisse, D
    Van Huyen, JPD
    Piketty, C
    Bloch, F
    Pialoux, G
    Belec, L
    Petite, JP
    Weiss, L
    Kazatchkine, M
    AIDS, 2000, 14 (07) : 839 - 844
  • [44] Bone mineral density is improved after 48 weeks combination therapy with interferon-α and ribavirin in patients with chronic hepatitis C.
    Redondo-Cerezo, E
    González-Calvín, J
    Martín-Vivaldi, R
    Nogueras, F
    Fernández-Pascual, R
    Escobar, F
    HEPATOLOGY, 2004, 40 (04) : 318A - 318A
  • [45] A reduced dose of ribavirin does not influence the virologic response during pegylated interferon alpha-2b and ribavirin combination therapy in patients with genotype 1 chronic hepatitis C
    You, Byung Chul
    Kim, Young Seok
    Kim, Hun il
    Kim, Se Hun
    Park, Seung Sik
    Seo, Yu Ri
    Kim, Sang Gyune
    Lee, Se Whan
    Kim, Hong Soo
    Jeong, Soung Won
    Jang, Jae Young
    Kim, Boo Sung
    CLINICAL AND MOLECULAR HEPATOLOGY, 2012, 18 (03) : 272 - 278
  • [46] Th1 response during ribavirin and interferon-α combination therapy in chronic hepatitis C
    Kobayashi, K
    Ueno, Y
    Kobayashi, Y
    Akahaned, T
    Satoh, S
    Kikuchi, K
    Okamoto, H
    Ishii, M
    Shimosegawa, T
    HEPATOLOGY RESEARCH, 2006, 34 (02) : 104 - 110
  • [47] Chronic hepatitis C in HIV-coinfected patients:: Feasibility and efficacy of interferon-α2b and ribavirin combination therapy
    Nasti, G
    di Gennaro, G
    Rizzardini, G
    Cadorin, L
    Tirelli, U
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2001, 26 (03) : 299 - 300
  • [48] Pegylated Interferon-α2a and Ribavirin versus Pegylated Interferon-α2b and Ribavirin in Chronic Hepatitis C A Meta-Analysis
    Flori, Nicolas
    Funakoshi, Natalie
    Duny, Yohan
    Valats, Jean-Christophe
    Bismuth, Michael
    Christophorou, Dimitri
    Daures, Jean-Pierre
    Blanc, Pierre
    DRUGS, 2013, 73 (03) : 263 - 277
  • [49] Diabetes mellitus reduces the therapeutic effectiveness of interferon-α2b plus ribavirin therapy in patients with chronic hepatitis C
    Konishi, Ichiro
    Horiike, Norio
    Hiasa, Yoichi
    Tokumoto, Yoshio
    Mashiba, Toshie
    Michitaka, Kojiro
    Miyake, Yasuyuki
    Nonaka, Suguru
    Joukou, Kouji
    Matsuura, Bunzo
    Onji, Morikazu
    HEPATOLOGY RESEARCH, 2007, 37 (05) : 331 - 336
  • [50] Combination therapy with daily interferon alpha and ribavirin in naive patients with chronic hepatitis C.
    Rothstein, KD
    Suvannasankha, A
    Digreggorio, K
    Gross, F
    Peikin, S
    Mushnick, A
    Deangelo, C
    Salowe, D
    Siegel, H
    Shaw, E
    Bond, K
    Manzarbeitia, C
    HEPATOLOGY, 1999, 30 (04) : 619A - 619A
12345